Trial Profile
A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Venglustat (Primary)
- Indications Fabry's disease
- Focus Therapeutic Use
- Acronyms Fabry Mono SRT
- Sponsors Genzyme Corporation; Sanofi
- 20 Sep 2016 Status changed from active, no longer recruiting to completed.
- 25 Mar 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 19 Nov 2015 Planned end date changed from 1 Nov 2016 to 1 Sep 2016, as reported by ClinicalTrials.gov.